{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T06:07:20Z","timestamp":1788934040551,"version":"build-2803163510"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["310030_219204"],"award-info":[{"award-number":["310030_219204"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["51NF40-141825"],"award-info":[{"award-number":["51NF40-141825"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004784","name":"Novartis Stiftung f\u00fcr Medizinisch-Biologische Forschung","doi-asserted-by":"publisher","award":["24C158"],"award-info":[{"award-number":["24C158"]}],"id":[{"id":"10.13039\/501100004784","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018694","name":"HORIZON EUROPE Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Bioeng. Biotechnol."],"abstract":"<jats:p>\n                    Chimeric antigen receptor (CAR) T cell therapies targeting B cell maturation antigen (BCMA) have shown unprecedented success in treating multiple myeloma (MM), yet long-term relapse remains a critical challenge, possible due to the protective influence of the bone marrow (BM) microenvironment. Current\n                    <jats:italic>in vitro<\/jats:italic>\n                    models often rely on simplistic 2D cocultures of CAR T and MM\u00a0cells, and fail to recapitulate the 3D structural and cellular complexity of the osteogenic niche, which is known to facilitate immune evasion. In this study, we aimed to develop a physiologically relevant 3D\n                    <jats:italic>in vitro<\/jats:italic>\n                    MM model using a perfusion bioreactor system, hydroxyapatite scaffolds, and osteogenically-differentiated human BM mesenchymal stromal cells. Our results demonstrate that this system effectively supports the engraftment and 3D clustering of MM\u00a0cells while successfully mimicking the suppressive effect of the tumor on osteogenic matrix deposition. Use of the platform to assess BCMA-targeted CAR T cell activity indicated that, while CAR T cells efficiently cleared circulating tumor cells in the fluidic phase, the 3D osteogenic niche provided a protective environment that blunted cytotoxic efficacy. This resistance was not associated with T cell recruitment, suggesting that the 3D niche provides complex protection. Our study provides a proof-of-concept for a humanized, dynamic cell culture platform capturing the influence of the BM niche-MM cell crosstalk on the efficacy of immunotherapy. The model represents a promising tool for evaluating next-generation CAR T cell potencies and for investigating associated resistance mechanisms.\n                  <\/jats:p>","DOI":"10.3389\/fbioe.2026.1860416","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:50:37Z","timestamp":1788933037000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A 3D engineered multiple myeloma niche for evaluating CAR T cell therapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Lorea","family":"Jordana-Urriza","sequence":"first","affiliation":[{"name":"Hemato-Oncology Program. Cima Universidad de Navarra. IdiSNA","place":["Pamplona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuele G.","family":"Muraro","sequence":"additional","affiliation":[{"name":"Tissue Engineering, Department of Biomedicine, University of Basel and University Hospital Basel","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Du","sequence":"additional","affiliation":[{"name":"Tissue Engineering, Department of Biomedicine, University of Basel and University Hospital Basel","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Lambrecht","sequence":"additional","affiliation":[{"name":"Tissue Engineering, Department of Biomedicine, University of Basel and University Hospital Basel","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Roberto","family":"Rodriguez-Madoz","sequence":"additional","affiliation":[{"name":"Hemato-Oncology Program. Cima Universidad de Navarra. IdiSNA","place":["Pamplona, Spain"]},{"name":"Centro de Investigacion Biomedica en Red de Cancer (CIBERONC)","place":["Madrid, Spain"]},{"name":"Cancer Center Clinica Universidad de Navarra (CCUN)","place":["Pamplona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Martin","sequence":"additional","affiliation":[{"name":"Tissue Engineering, Department of Biomedicine, University of Basel and University Hospital Basel","place":["Basel, Switzerland"]},{"name":"Tissue Engineering, Department of Biomedical Engineering, University of Basel","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Garc\u00eda-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Tissue Engineering, Department of Biomedicine, University of Basel and University Hospital Basel","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e150807","DOI":"10.1172\/JCI150807","article-title":"CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome","volume":"132","author":"Arcangeli","year":"2022","journal-title":"J. Clin. Investigation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/sj.leu.2404466","article-title":"Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma","volume":"21","author":"Arnulf","year":"2007","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1182\/blood","article-title":"Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma","volume":"101","author":"Bisping","year":"2003","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"20417314211044855","DOI":"10.1177\/20417314211044855","article-title":"Engineering of fully humanized and vascularized 3D bone marrow niches sustaining undifferentiated human cord blood hematopoietic stem and progenitor cells","volume":"12","author":"Born","year":"2021","journal-title":"J. Tissue Eng."},{"key":"B6","doi-asserted-by":"publisher","first-page":"eabd4344","DOI":"10.1126\/sciimmunol.abd4344","article-title":"A crosstalk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity","volume":"6","author":"Boulch","year":"2021","journal-title":"Sci. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"E5688","DOI":"10.1073\/pnas.1805440115","article-title":"In vitro biomimetic engineering of a human hematopoietic niche with functional properties","volume":"115","author":"Bourgine","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B8","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1089\/ten.tec.2017.0467","article-title":"Endosteal and perivascular subniches in a 3D bone marrow model for multiple myeloma","volume":"24","author":"Braham","year":"2018","journal-title":"Tissue Eng. Part C Methods"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1182\/blood-2008-02-133751","article-title":"Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis","volume":"113","author":"Che","year":"2009","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"115973","DOI":"10.1016\/j.celrep.2025.115973","article-title":"CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients","volume":"44","author":"Cook","year":"2025","journal-title":"Cell Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/sj.leu.2404621","article-title":"Bone marrow mesenchymal stem cells are abnormal in multiple myeloma","volume":"21","author":"Corre","year":"2007","journal-title":"Leukemia"},{"key":"B12","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1182\/blood.V93.5.1658","article-title":"Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines","volume":"93","author":"Damiano","year":"1999","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41590-021-00931-3","article-title":"The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape","volume":"22","author":"de Jong","year":"2021","journal-title":"Nat. Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.biomaterials.2015.09.017","article-title":"3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma","volume":"73","author":"de la Puente","year":"2015","journal-title":"Biomaterials"},{"key":"B16","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1046\/j.1365-2141.2002.03257.x","article-title":"Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity","volume":"116","author":"Epstein","year":"2002","journal-title":"Br. J. Haematol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1038\/leu.2009.65","article-title":"Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors","volume":"23","author":"Garayoa","year":"2009","journal-title":"Leukemia"},{"key":"B18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/cancers","article-title":"The role of tumor microenvironment in multiple Myeloma development and progression","volume":"13","author":"Garc\u00eda-Ortiz","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv."},{"key":"B20","doi-asserted-by":"publisher","first-page":"123016","DOI":"10.1016\/j.biomaterials.2024.123016","article-title":"Multi-niche human bone marrow on-a-chip for studying the interactions of adoptive CAR-T cell therapies with multiple myeloma","volume":"316","author":"Ghoshal","year":"2025","journal-title":"Biomaterials"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1016\/j.ajpath.2016.04.003","article-title":"Effects of IL-8 Up-Regulation on cell survival and osteoclastogenesis in multiple myeloma","volume":"186","author":"Herrero","year":"2016","journal-title":"Am. J. Pathology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1242\/dmm.008961","article-title":"Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models","volume":"5","author":"Hu","year":"2012","journal-title":"DMM Dis. Models Mech."},{"key":"B23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1089\/ten.tec.2023.0374","article-title":"Liquid overlay and collagen-based three-dimensional models for in vitro investigation of multiple myeloma","volume":"30","author":"Ilic","year":"2024","journal-title":"Tissue Eng. Part C Methods"},{"key":"B24","doi-asserted-by":"publisher","first-page":"77326","DOI":"10.18632\/oncotarget.12643","article-title":"A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications","volume":"7","author":"Jakubikova","year":"2016","journal-title":"Oncotarget"},{"key":"B25","doi-asserted-by":"publisher","first-page":"100203","DOI":"10.1016\/j.bneo.2026.100203","article-title":"Single-Cell multiomics reveals regulatory mechanisms of CAR T cell persistence and dysfunction in multiple myeloma","volume":"3","author":"Jordana-Urriza","year":"2026","journal-title":"Blood Neoplasia"},{"key":"B26","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1046\/j.1365-2141.2000.01845.x","article-title":"Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts","volume":"108","author":"Karadag","year":"2000","journal-title":"Br. J. Haematol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/imr.12233","article-title":"Targeting the bone marrow microenvironment in multiple myeloma","volume":"263","author":"Kawano","year":"2015","journal-title":"Immunol. Rev."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41598-021-04296-3","article-title":"The differential effects of tumor burdens on predicting the net benefits of ssCART-19 cell treatment on r\/r B-ALL patients","volume":"12","author":"Li","year":"2022","journal-title":"Sci. Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"12888","DOI":"10.3390\/ijms232112888","article-title":"Patient-Derived multiple myeloma 3D models for personalized Medicine\u2014Are we there yet?","volume":"23","author":"Louren\u00e7o","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2147\/ITT.S503984","article-title":"A High-Throughput, three-dimensional multiple myeloma model recapitulating tumor-stroma interactions for CAR-Immune cell-mediated cytotoxicity assay","volume":"14","author":"Luanpitpong","year":"2025","journal-title":"Immunotargets Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B34","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1101\/2021.05.07.443194","article-title":"Decade-long leukemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1111\/bjh.19896","article-title":"Are we there yet? CAR-T therapy in multiple myeloma","volume":"205","author":"Mirvis","year":"2024","journal-title":"Br. J. Haematol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1158\/1078-0432.CCR-22-0164","article-title":"Phenotypic composition of commercial Anti-CD19 CAR T cells affects in vivo expansion and disease response in patients with large B-cell lymphoma","volume":"28","author":"Monfrini","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/nejmoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/978-1-0716-3593-3_10","article-title":"Hypoxic 3D tumor model for evaluating of CAR-T cell therapy in vitro","volume":"2748","author":"Oh","year":"2024","journal-title":"Methods Mol. Biol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S1470-2045(23)00222-X","article-title":"Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study","volume":"24","author":"Oliver-Cald\u00e9s","year":"2023","journal-title":"Lancet Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"6344344","DOI":"10.1155\/2021\/6344344","article-title":"Bone marrow neutrophils of multiple myeloma patients exhibit myeloid-derived suppressor cell activity","volume":"2021","author":"Petersson","year":"2021","journal-title":"J. Immunol. Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/nejmoa1817226","article-title":"Anti-BCMA CAR T-Cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1182\/blood-2014-02-558007","article-title":"Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model","volume":"124","author":"Reagan","year":"2014","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/nejmoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat. Commun."},{"key":"B45","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/nejmoa2303379","article-title":"Cilta-cel or standard care in Lenalidomide-Refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41571-019-0184-6","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2249.2011.04327.x","article-title":"Immunomodulatory properties and therapeutic application of mesenchymal stem cells","volume":"164","author":"Shi","year":"2011","journal-title":"Clin. Exp. Immunol."},{"key":"B48","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000848640.53562.8f","article-title":"P1446 phase I study data update of PHE885, a fully human BCMA-directed CAR-T cell therapy manufactured using the T-ChargeTM platform for patients with relapsed\/refractory (R\/R) Multiple Myeloma (MM)","volume-title":"Gene Therapy, Cellular Immunotherapy and Vaccination","author":"Sperling","year":"2022"},{"key":"B49","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1002\/jbmr.4404","article-title":"A functional three-dimensional microphysiological human model of myeloma bone disease","volume":"36","author":"Visconti","year":"2020","journal-title":"J. Bone Mineral Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1182\/blood-2014-03-562439","article-title":"Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.4049\/jimmunol.153.6.2515","article-title":"Induction of IL-8 expression in T cells uses the CD28 costimulatory pathway","volume":"153","author":"Wechsler","year":"1994","journal-title":"J. Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e2100884","DOI":"10.1002\/adhm.202100884","article-title":"A 3D-Bioprinted multiple myeloma model","volume":"11","author":"Wu","year":"2022","journal-title":"Adv. Healthc. Mater."},{"key":"B54","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41467-023-44648-3","article-title":"Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma","volume":"15","author":"Yang","year":"2024","journal-title":"Nat. Commun."},{"key":"B56","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1089\/ten.tec.2013.0490","article-title":"Patient-Specific 3D microfluidic tissue model for multiple myeloma","volume":"20","author":"Zhang","year":"2014","journal-title":"Tissue Eng. Part C Methods"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2022.927153","article-title":"CAR-T cell therapy in hematological malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1002\/jbmr.2231","article-title":"Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKL signaling pathways","volume":"29","author":"Zheng","year":"2014","journal-title":"J. Bone Mineral Res."}],"container-title":["Frontiers in Bioengineering and Biotechnology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2026.1860416\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:50:39Z","timestamp":1788933039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2026.1860416\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":58,"alternative-id":["10.3389\/fbioe.2026.1860416"],"URL":"https:\/\/doi.org\/10.3389\/fbioe.2026.1860416","relation":{},"ISSN":["2296-4185"],"issn-type":[{"value":"2296-4185","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1860416"}}